TxCell Enrolls First Patient for Phase IIb Crohn’s Disease Study

TxCell Enrolls First Patient for Phase IIb Crohn’s Disease Study
TxCell SA, a biotechnology company specializing in developing novel immunotherapies for severe chronic inflammatory and autoimmune diseases, has just announced the enrollment and dosing of the first patient in the Phase IIb clinical study of Ovasave®, indicated for the treatment of refractory Crohn’s disease. Ovasave® (ovalbumin-specific autologous Treg cells) is the company’s lead product for

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *